AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15564386 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (usual care, relaxation, medication)
Number of subjects: 143
Study 11983663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (B)
Number of subjects: 51
Study 11983663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (R)
Number of subjects: 51
Study 8038232 — intervention group
Group type: EXPERIMENTAL
Intervention: NADPH-oxidase activation
Number of subjects: 0
Study 8038232 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron transfer mechanisms
Number of subjects: 0
Study 8038232 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular pathology
Number of subjects: 0
Study 3069051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised beclomethasone dipropionate
Number of subjects: 44
Study 3069051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31474753 — intervention group
Group type: EXPERIMENTAL
Intervention: EFD 0.05 mJ/mm2, two sessions per week (Group A)
Number of subjects: 97
Study 31474753 — intervention group
Group type: EXPERIMENTAL
Intervention: EFD 0.05 mJ/mm2, three sessions per week (Group B)
Number of subjects: 97
Study 31474753 — intervention group
Group type: EXPERIMENTAL
Intervention: EFD 0.10 mJ/mm2, two sessions per week (Group C)
Number of subjects: 97
Study 31474753 — intervention group
Group type: EXPERIMENTAL
Intervention: EFD 0.10 mJ/mm2, three sessions per week (Group D)
Number of subjects: 97
Study 31444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal®
Number of subjects: 15
Study 31444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal®Seal™
Number of subjects: 15
Study 31444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Protecto®CaF2Nano
Number of subjects: 15
Study 31444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond™ XT
Number of subjects: 15
Study 28341877 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisolone at 0.5 mg/kg for 5 days during URTI
Number of subjects: 48
Study 28341877 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days during URTI
Number of subjects: 48
Study 25605425 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasive device (AAD) with amino acid glycine powder
Number of subjects: 25
Study 25605425 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement (MDA) using carbon curettes and antiseptic therapy with chlorhexidine digluconate
Number of subjects: 25
Study 23312291 — intervention group
Group type: EXPERIMENTAL
Intervention: neuropsychological computer training for 14 days, 25‐35 min per day
Number of subjects: 43
Study 23312291 — intervention group
Group type: COMPARATOR
Intervention: standard treatment according to Federal and local medical recommendations
Number of subjects: 43
Study 22070868 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab in combination with oxaliplatin- or irinotecan-based chemotherapy
Number of subjects: 1124
Study 19849685 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 86
Study 19849685 — intervention group
Group type: COMPARATOR
Intervention: CTrach
Number of subjects: 86
Study 16205905 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ug clonidine intra-articularly
Number of subjects: 69
Study 16205905 — intervention group
Group type: COMPARATOR
Intervention: 150 ug clonidine intravenously
Number of subjects: 69
Study 16205905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 14998222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 14998222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11419380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preidentification questions including a new question about belief in ability to reject a target-absent lineup
Number of subjects: 138
Study 11419380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 138
Study 9240888 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hydroxy-3-indole acetic acid (5-OH IAA) levels in colicky infants
Number of subjects: 16
Study 9240888 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 16
Study 8100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 micrograms/kg and atipamezole 50 micrograms/kg
Number of subjects: 72
Study 8100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 micrograms/kg and saline
Number of subjects: 72
Study 8100428 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.15 mg/kg and saline
Number of subjects: 72
Study 3209717 — intervention group
Group type: EXPERIMENTAL
Intervention: DA agonist (bromocriptine 5 mg orally)
Number of subjects: 15
Study 3209717 — intervention group
Group type: EXPERIMENTAL
Intervention: DA antagonist (haloperidol 5 mg intravenously)
Number of subjects: 15
Study 3209717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic agonist (physostigmine 2 mg intravenously)
Number of subjects: 15
Study 3209717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic antagonist (benztropine 4 mg intravenously)
Number of subjects: 15
Study 3209717 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 15
Study 31302525 — intervention group
Group type: EXPERIMENTAL
Intervention: MARIGOLD intervention
Number of subjects: 137
Study 31302525 — intervention group
Group type: COMPARATOR
Intervention: Daily emotion reporting
Number of subjects: 137
Study 31302525 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 137
Study 31302525 — intervention group
Group type: EXPERIMENTAL
Intervention: MARIGOLD plus online discussion board (ODB)
Number of subjects: 137
Study 31302525 — intervention group
Group type: EXPERIMENTAL
Intervention: MARIGOLD plus virtual badges (VB)
Number of subjects: 137
Study 31302525 — intervention group
Group type: EXPERIMENTAL
Intervention: MARIGOLD plus facilitator contact (FC)
Number of subjects: 137
Study 28315016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling training exercises
Number of subjects: 50
Study 28315016 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 50
Study 25558034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 21
Study 25558034 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 21
Study 23627498 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency format (X out of 100)
Number of subjects: 154
Study 23627498 — intervention group
Group type: COMPARATOR
Intervention: Frequency format plus graphical display (10 × 10 human icons)
Number of subjects: 154
Study 21295835 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (25 mg im, twice daily for 4 days)
Number of subjects: 32
Study 21295835 — intervention group
Group type: COMPARATOR
Intervention: eCG (1000 IU as a single i.m. dose)
Number of subjects: 32
Study 19703336 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 38
Study 19703336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17768187 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated preoperative and postoperative rehabilitation
Number of subjects: 100
Study 17768187 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 100
Study 15117400 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 191
Study 15117400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 191
Study 11471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 137
Study 11471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of melatonin 5 mg and zolpidem 10 mg
Number of subjects: 137
Study 11471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 137
Study 11471907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 9555553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection, followed by 11 additional monthly instillations of epirubicin
Number of subjects: 148
Study 9555553 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection
Number of subjects: 148
Study 8177458 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 40
Study 8177458 — intervention group
Group type: EXPERIMENTAL
Intervention: Estro-progestin therapy
Number of subjects: 40
Study 8177458 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 40
Study 3308192 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital cobalt irradiation combined with retrobulbar methylprednisolone acetate (14 bilateral injections at 20-30 d intervals)
Number of subjects: 44
Study 3308192 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy with systemic corticosteroids and orbital radiotherapy
Number of subjects: 44
Study 31774544 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized-isotretinoin 32 mg (fed state)
Number of subjects: 89
Study 31774544 — intervention group
Group type: COMPARATOR
Intervention: Lidose-isotretinoin 40 mg (fed state)
Number of subjects: 89
Study 31774544 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized-isotretinoin 32 mg (fasted state)
Number of subjects: 89
Study 31774544 — intervention group
Group type: COMPARATOR
Intervention: Lidose-isotretinoin 40 mg (fasted state)
Number of subjects: 89
Study 29506967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered Web-based questionnaires (SAQ-Web)
Number of subjects: 11140
Study 29506967 — intervention group
Group type: COMPARATOR
Intervention: Self-administered paper-based questionnaires (SAQ-paper)
Number of subjects: 11140
Study 28231779 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical reduction and fixation of the posterior fragment via the posterolateral approach (n=42)
Number of subjects: 84
Study 28231779 — intervention group
Group type: COMPARATOR
Intervention: No fixation of the posterior fragment (n=42)
Number of subjects: 84
Study 25732095 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (participants who selected the color of golf balls)
Number of subjects: 0
Study 25732095 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (participants who made choices unrelated to the practice task)
Number of subjects: 0
Study 25732095 — intervention group
Group type: COMPARATOR
Intervention: Yoked group (participants who received the same colored golf balls as the choice group)
Number of subjects: 0
Study 25732095 — intervention group
Group type: COMPARATOR
Intervention: Yoked group (participants who were informed about subsequent tasks and painting)
Number of subjects: 0
Study 23941667 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL protocol for occupational therapists
Number of subjects: 124
Study 23941667 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 124
Study 22087067 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual social facilitation with competitive avatars
Number of subjects: 14
Study 22087067 — intervention group
Group type: COMPARATOR
Intervention: Baseline exercise effort (pre-avatar)
Number of subjects: 14
Study 18337740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0
Study 16735793 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 40
Study 16735793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16735793 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 40
Study 16735793 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol and Placebo
Number of subjects: 40
Study 14671175 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/6 wk TU plus 20 mg/d CPA
Number of subjects: 24
Study 14671175 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/8 wk TU plus 2 mg/d CPA
Number of subjects: 24
Study 14671175 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg/8 wk TU plus placebo
Number of subjects: 24
Study 14671175 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 10882331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 97
Study 10882331 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg granisetron
Number of subjects: 97
Study 10882331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron + DEX
Number of subjects: 97
Study 10882331 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg granisetron + DEX
Number of subjects: 97
Study 8993943 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily)
Number of subjects: 60
Study 8993943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg daily)
Number of subjects: 60
Study 8993943 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Ciprofibrate combination
Number of subjects: 60
Study 8993943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1730327 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 4
Study 1730327 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) + ethinyl estradiol (E2)
Number of subjects: 4
Study 1730327 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin
Number of subjects: 4
Study 1730327 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 4
Study 3881968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (0.75 mg, 1.5 mg, or 2.25 mg)
Number of subjects: 28
Study 3881968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30316547 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised manual therapy plus guideline-based advice (10 sessions)
Number of subjects: 64
Study 30316547 — intervention group
Group type: COMPARATOR
Intervention: Advice alone (2 sessions)
Number of subjects: 64
Study 29199629 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP-Ed intervention
Number of subjects: 328
Study 24189485 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation
Number of subjects: 65
Study 24189485 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation
Number of subjects: 65
Study 26462353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sommerlad technique
Number of subjects: 54
Study 22556131 — intervention group
Group type: COMPARATOR
Intervention: Suprasensory stimulation
Number of subjects: 15
Study 22556131 — intervention group
Group type: COMPARATOR
Intervention: Subsensory stimulation
Number of subjects: 15
Study 20838035 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet V (increased vegetable consumption)
Number of subjects: 57
Study 20838035 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased cereal consumption)
Number of subjects: 57
Study 20838035 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total calcium intake among women with initial calcium intake below the 50th percentile
Number of subjects: 57
Study 16236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 401
Study 16236320 — intervention group
Group type: COMPARATOR
Intervention: Lithium (300-1800 mg/d)
Number of subjects: 401
Study 15124783 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion primer (Composite Activator) and resin (CA)
Number of subjects: 60
Study 15124783 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane (EspeSil) and resin (SIL-MP)
Number of subjects: 60
Study 15124783 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane, adhesive primer, and resin (Clearfil Repair) (CF)
Number of subjects: 60
Study 15124783 — intervention group
Group type: EXPERIMENTAL
Intervention: Air particle-abrading (CoJet), silane, and resin (CJ-SIL-MP)
Number of subjects: 60
Study 15124783 — intervention group
Group type: COMPARATOR
Intervention: Resin (Scotchbond Multipurpose Resin) only
Number of subjects: 60
Study 11822473 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.9 g x kg lean tissue mass(-1) x day(-1); n = 17)
Number of subjects: 31
Study 11822473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9 g maltodextrin x kg lean tissue mass(-1) x day(-1); n = 14)
Number of subjects: 31
Study 9793665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 90
Study 9793665 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 90
Study 7746123 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment (1 g of ciprofloxacin in a single daily dose for 2 days)
Number of subjects: 57
Study 7746123 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (1 g of ciprofloxacin in two daily doses for 5 days)
Number of subjects: 57
Study 2643037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 602
Study 2643037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 602
Study 2643037 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 602
Study 2643037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily (with NSAIDs)
Number of subjects: 602
Study 2643037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (with NSAIDs)
Number of subjects: 602
Study 2643037 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (with NSAIDs)
Number of subjects: 602
Study 2643037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole groups (overall)
Number of subjects: 602
Study 1172813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of allopurinol (300 mg)
Number of subjects: 20
Study 1172813 — intervention group
Group type: COMPARATOR
Intervention: Divided doses of allopurinol (100 mg three times a day)
Number of subjects: 20
Study 31469508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose drug dispensing (MDD)
Number of subjects: 179
Study 31469508 — intervention group
Group type: COMPARATOR
Intervention: Manual dispensing (Control)
Number of subjects: 179
Study 31307833 — intervention group
Group type: EXPERIMENTAL
Intervention: CND 32 mg/RSV 20 mg
Number of subjects: 219
Study 31307833 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV 20 mg
Number of subjects: 219
Study 31307833 — intervention group
Group type: COMPARATOR
Intervention: CND 32 mg
Number of subjects: 219
Study 28578844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Mobility (DM) implant
Number of subjects: 24
Study 28578844 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Bearing (SB) implant
Number of subjects: 24
Study 28578844 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (CTRLs)
Number of subjects: 24
Study 26003019 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Integrity zotarolimus-eluting stents
Number of subjects: 1811
Study 26003019 — intervention group
Group type: COMPARATOR
Intervention: Promus Element everolimus-eluting stents
Number of subjects: 1811
Study 26003019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 1811
Study 26003019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain after 12 months
Number of subjects: 1811
Study 24085378 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise therapy (90 min under physiotherapist guidance)
Number of subjects: 209
Study 24085378 — intervention group
Group type: COMPARATOR
Intervention: Home exercise therapy
Number of subjects: 209
Study 24085378 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise therapy
Number of subjects: 209
Study 21619618 — intervention group
Group type: EXPERIMENTAL
Intervention: First fitted amputees (FFA)
Number of subjects: 28
Study 21619618 — intervention group
Group type: EXPERIMENTAL
Intervention: First fitted amputees (FFA) standing on the non-affected leg
Number of subjects: 28
Study 21619618 — intervention group
Group type: COMPARATOR
Intervention: Skilled prosthetic users (SPU)
Number of subjects: 28
Study 19114852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg twice daily
Number of subjects: 0
Study 19114852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg twice daily
Number of subjects: 0
Study 19114852 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care regimen
Number of subjects: 0
Study 15575933 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily for 8 days)
Number of subjects: 0
Study 15575933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg twice daily for 8 days)
Number of subjects: 0
Study 15575933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15575933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study 15575933 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Fluticasone
Number of subjects: 0
Study 11874209 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113
Study 11874209 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 113
Study 11874209 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 113
Study 10460064 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus, 9 mg/kg/h infusion for 1 hour)
Number of subjects: 24
Study 10460064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soybean emulsion, same volume as propofol)
Number of subjects: 24
Study 7796591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 0
Study 7796591 — intervention group
Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 0
Study 2135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy (10 week course)
Number of subjects: 18
Study 498955 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy with splenectomy after multiple chemotherapy
Number of subjects: 182